The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma

被引：22

作者：

Barraclough, Allison ^{[1
,2
]}

Bishton, Mark ^{[3
]}

Cheah, Chan Y. ^{[4
,5
]}

Villa, Diego ^{[6
,7
]}

Hawkes, Eliza A. ^{[8
,9
]}

机构：

[1] Austin Hlth, Dept Haematol, Melbourne, Vic, Australia

[2] Fiona Stanley Hosp, Dept Haematol, Perth, WA, Australia

[3] Nottingham City Hosp, Dept Haematol, Nottingham, England

[4] Sir Charles Gairdner Hosp, Dept Haematol, Perth, WA, Australia

[5] Univ Western Australia, Med Sch, Perth, WA, Australia

[6] British Columbia Canc, Ctr Lymphoid Canc, Vancouver, BC, Canada

[7] Univ British Columbia, Vancouver, BC, Canada

[8] Austin Hlth, Olivia Newton John Canc Res & Wellness Ctr, Dept Med Oncol & Haematol, Melbourne, Vic, Australia

[9] Eastern Hlth, Dept Med Oncol & Haematol, Melbourne, Vic, Australia

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 195卷 / 01期

关键词：

lymphoma; lymphoproliferative disease; non‐ Hodgkin lymphoma; lymphoid malignancies; B-CELL LYMPHOMA; EUROPEAN-AMERICAN CLASSIFICATION; HIGH-DOSE THERAPY; PROGNOSTIC VALUE; AUTOLOGOUS TRANSPLANTATION; MAINTENANCE RITUXIMAB; HISTOLOGIC GRADE; EXPRESSION; BCL6; ANTHRACYCLINE;

D O I：

10.1111/bjh.17404

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Grade 3B follicular lymphoma (G3B FL) is rare, accounting for only 5-10% of FLs. Not only has it been routinely excluded from clinical trials, but data published on diagnosis, outcomes, choice of therapies and role of imaging are conflicting. With the advent of increasingly diverse treatment options for low-grade (G1-3A) FL, and the molecular subcategorisation of high-grade B-cell lymphomas, characterisation and treatment of G3B FL is ever more important as extrapolation of data becomes more difficult. New data have emerged exploring unique genetic characteristics, specific features on positron emission tomography imaging, choice of therapy, and outcomes of G3B FL in the current era. The present review will summarise and appraise these new data, and offer recommendations based on current evidence.

引用

页码：15 / 24

页数：10

共 79 条

[61] The CUP trial: A randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin's lymphoma (NHL) [J].

Schouten, HC ;

Kvaloy, S ;

Sydes, M ;

Qian, W ;

Fayers, PM .

ANNALS OF ONCOLOGY, 2000, 11 :91-94

[62] Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial [J].

Sehn, Laurie H. ;

Chua, Neil ;

Mayer, Jiri ;

Dueck, Gregg ;

Trneny, Marek ;

Bouabdallah, Kamal ;

Fowler, Nathan ;

Delwail, Vincent ;

Press, Oliver ;

Salles, Gilles ;

Gribben, John ;

Lennard, Anne ;

Lugtenburg, Pieternella J. ;

Dimier, Natalie ;

Wassner-Fritsch, Elisabeth ;

Fingerle-Rowson, Guenter ;

Cheson, Bruce D. .

LANCET ONCOLOGY, 2016, 17 (08) :1081-1093

[63] A PREDICTIVE MODEL FOR AGGRESSIVE NON-HODGKINS-LYMPHOMA [J].

SHIPP, MA ;

HARRINGTON, DP ;

ANDERSON, JR ;

ARMITAGE, JO ;

BONADONNA, G ;

BRITTINGER, G ;

CABANILLAS, F ;

CANELLOS, GP ;

COIFFIER, B ;

CONNORS, JM ;

COWAN, RA ;

CROWTHER, D ;

DAHLBERG, S ;

ENGELHARD, M ;

FISHER, RI ;

GISSELBRECHT, C ;

HORNING, SJ ;

LEPAGE, E ;

LISTER, TA ;

MEERWALDT, JH ;

MONTSERRAT, E ;

NISSEN, NI ;

OKEN, MM ;

PETERSON, BA ;

TONDINI, C ;

VELASQUEZ, WA ;

YEAP, BY .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (14) :987-994

[64] Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy [J].

Shustik, J. ;

Quinn, M. ;

Connors, J. M. ;

Gascoyne, R. D. ;

Skinnider, B. ;

Sehn, L. H. .

ANNALS OF ONCOLOGY, 2011, 22 (05) :1164-1169

[65] Follicular lymphoma international prognostic index [J].

Solal-Céligny, P ;

Roy, P ;

Colombat, P ;

White, J ;

Armitage, JO ;

Arranz-Saez, R ;

Au, WY ;

Bellei, M ;

Brice, P ;

Caballero, D ;

Coiffier, B ;

Conde-Garcia, E ;

Doyen, C ;

Federico, M ;

Fisher, RI ;

Garcia-Conde, JF ;

Guglielmi, C ;

Hageenbeek, A ;

Haïoun, C ;

LeBlanc, M ;

Lister, AT ;

Lopez-Guillermo, A ;

McLaughlin, P ;

Milpied, N ;

Morel, P ;

Mounier, N ;

Proctor, SJ ;

Rohatiner, A ;

Smith, P ;

Soubeyran, P ;

Tilly, H ;

Vitolo, U ;

Zinzani, PL ;

Zucca, E ;

Montserrat, E .

BLOOD, 2004, 104 (05) :1258-1265

[66] Bone involvement on PET/CT predicts event-free survival in follicular lymphoma Grade 3B [J].

St-Pierre, Frederique ;

Broski, Stephen M. ;

LaPlant, Betsy R. ;

Ristow, Kay ;

Macon, William R. ;

Habermann, Thomas M. ;

Witzig, Thomas E. .

BRITISH JOURNAL OF HAEMATOLOGY, 2020, 191 (02) :E41-E43

[67] Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP [J].

Strati, Paolo ;

Fowler, Nathan ;

Pina-Oviedo, Sergio ;

Medeiros, L. Jeffrey ;

Overman, Michael J. ;

Romaguera, Jorge E. ;

Nastoupil, Loretta ;

Wang, Michael ;

Hagemeister, Fredrick B. ;

Rodriguez, Alma ;

Oki, Yasuhiro ;

Westin, Jason ;

Turturro, Francesco ;

Neelapu, Sattva S. ;

Fayad, Luis .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (01) :E103-E108

[68]

Swerdlow SH., 2008, WHO CLASSIFICATION T

[69] The 2016 revision of the World Health Organization classification of lymphoid neoplasms [J].

Swerdlow, Steven H. ;

Campo, Elias ;

Pileri, Stefano A. ;

Harris, Nancy Lee ;

Stein, Harald ;

Siebert, Reiner ;

Advani, Ranjana ;

Ghielmini, Michele ;

Salles, Gilles A. ;

Zelenetz, Andrew D. ;

Jaffe, Elaine S. .

BLOOD, 2016, 127 (20) :2375-2390

[70] Significant high expression of CD23 in follicular lymphoma of the inguinal region [J].

Thorns, C. ;

Kalies, K. ;

Fischer, U. ;

Hoefig, K. ;

Krokowski, M. ;

Feller, A. C. ;

Merz, H. ;

Bernd, H-W .

HISTOPATHOLOGY, 2007, 50 (06) :716-719

← 1 2 3 4 5 6 7 8 →